There were 2,514 press releases posted in the last 24 hours and 359,560 in the last 365 days.

David Steenblock, D.O., Uses EDTA Chelation for a Variety of Regenerative Medicine Therapies

SAN CLEMENTE, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- David Steenblock, an osteopathic physician based in San Clemente, CA, is uniquely qualified to address toxicity in the human body through his use of EDTA Chelation Therapy. 

Dr. Steenblock uses EDTA (EthyleneDiamineTetraAcetic Acid) Chelation Therapy, a procedure that removes heavy metals from the blood, and consistently improves blood flow and relieves symptoms associated with atherosclerosis in over 80% of patients treated. 

“It’s been observed that patients being treated for acute lead intoxification with EDTA with cardiovascular disease, showed improved stress tolerance and less chest pain with physical exertion, “ said Dr. Steenblock. 

Dr. Steenblock believes that the benefits of EDTA chelation can improve circulation; reduce cholesterol levels, decrease high blood pressure; and lower insulin requirements in diabetics.

In addition, Dr. Steenblock uses EDTA Chelation Therapy with a combination of hyperbaric oxygen therapy, leading to significant neurologic improvements for stroke patients.

Dr. David Steenblock is a leading-edge physician in many fields of medicine, from stroke care, to acute brain trauma, to generative and cell-based medicine in the treatment of ALS, Cerebral Palsy and other chronic and degenerative diseases.  For more information about Dr. Steenblock’s work in stem cell therapies, visit www.stemcellmd.org

CONTACT:

Irene Doti
irene@dotihealthcare.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.